Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Low Rates of Vancomycin Use in Febrile Neutropenia: A Multicenter Study

André Domingues Pereira, MD, Jessica Fernandes Ramos, MD PhD, Mariana Guarana, MD, Simone A Nouér, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 4755.

https://doi.org/10.1182/blood-2019-132271

Published: 2019

Journal Articles

Carbapenemase-Producing Enterobacteriaceae (CPE) Bloodstream Infections (BSI) in Neutropenic Patients (pts) with Acute Leukemia (AL). Comparison of 2 Strategies

Marcos Lemos, MD, Rebeca Brito, MD, Margarida Fevereiro, MD, Mariana L. Fernandes, MD, Filipa Saraiva, MD, Susana G Pereira, MD, Leonor Sarmento, MD, Alexandra Monteiro, MD, Aida B Sousa, MD

Blood (2019) 134 (Supplement_1): 1333.

https://doi.org/10.1182/blood-2019-124986

Published: 2019

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Kenichi Ishizawa, MD PhD, Kensuke Usuki, MD PhD, Kiyoshi Ando, MD PhD, Yasunori Ueda, MD PhD, Toru Kiguchi, MD PhD, Naokuni Uike, MD PhD, Yasushi Onishi, MD PhD, Hiroatsu Iida, MD PhD

Blood (2016) 128 (22): 5538.

https://doi.org/10.1182/blood.V128.22.5538.5538

Published: 2016

Journal Articles

In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013

Urshila Durani, MD MPH, Ronald S. Go, MD

Blood (2016) 128 (22): 4762.

https://doi.org/10.1182/blood.V128.22.4762.4762

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

Febrile Neutropenia Outcome in Hemato-Oncological Patients after the Implementation of an Adapted Therapeutic Protocol at a University Hospital in Uruguay

Sofia Grille, MD PhD, Boada Matilde, MD, Regina Guadagna, MD, Maria Noel Spangenber, MD, Felipe Lemos, MD, Mariana Stevenazzi, MD, Lilian Diaz, MD, Cecilia Guillermo, MD

Blood (2015) 126 (23): 4471.

https://doi.org/10.1182/blood.V126.23.4471.4471

Published: 2015

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Mathias Witzens-Harig, MD, Ulrich Keller, Andreas Viardot, MD, Christian Buske, MD, Anne Crombé, Elisabeth Hoenig, Julia Meissner, MD, Anthony D Ho, MD, Reinhard Marks, Martin H. Dreyling, MD PhD, Georg Hess, MD

Blood (2015) 126 (23): 2727.

https://doi.org/10.1182/blood.V126.23.2727.2727

Published: 2015

Journal Articles

Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications

Anna Schuck, MD, Marie Götte, Judith Neukirchen, MD, Andrea Kuendgen, MD, Norbert Gattermann, MD, Guido Kobbe, MD, Ulrich Germing, MD, Rainer Haas, MD

Blood (2015) 126 (23): 1684.

https://doi.org/10.1182/blood.V126.23.1684.1684

Published: 2015

Journal Articles

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Shuo Ma, MD PhD, Amy Kimball, MD PhD, Mary Beth Tombes, RN, Ellen Shrader, BS, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, RN, BSN, April Dean, BS, Sarah Conine, PhD, Heidi Sankala, PhD, John D. Roberts, MD, Thomas C. Shea, MD, Steven Grant, MD

Blood (2014) 124 (21): 3050.

https://doi.org/10.1182/blood.V124.21.3050.3050

Published: 2014

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Caitlin Driscoll, Ilene Galinsky, ANP, Martha Wadleigh, MD, David P. Steensma, MD, David Avigan, MD, Philip C. Amrein, MD, Suiyang Liu, James D. Griffin, MD, Steven L. McAfee, MD, Eyal C. Attar, MD, Karen K. Ballen, MD, Edward Fox, PhD, Daniel J. DeAngelo, MD, PhD

Blood (2012) 120 (21): 3627.

https://doi.org/10.1182/blood.V120.21.3627.3627

Published: 2012

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.

Hervé Ghesquières, MD, Roch Houot, MD, Céline Ferlay, Catherine Sebban, MD, Thérèse Gargi, CRA, Irène Philip, MD, Pierre Biron, MD, Isabelle Ray-Coquard, MD, Jean-Yves Blay, MD,PhD

Blood (2006) 108 (11): 2984.

https://doi.org/10.1182/blood.V108.11.2984.2984

Published: 2006

Journal Articles

Novel Risk Factors for Venous Thromboembolism (VTE): A Population-Based Case-Control Study.

John A. Heit, MD, Sara A. Farmer, BS, Tanya M. Petterson, MS, Kent R. Bailey, PhD, L. Joseph Melton, III, MD, M.P.H.

Blood (2005) 106 (11): 1618.

https://doi.org/10.1182/blood.V106.11.1618.1618

Published: 2005

NARROW

Low Rates of Vancomycin Use in Febrile Neutropenia: A Multicenter Study

Carbapenemase-Producing Enterobacteriaceae (CPE) Bloodstream Infections (BSI) in Neutropenic Patients (pts) with Acute Leukemia (AL). Comparison of 2 Strategies

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Febrile Neutropenia Outcome in Hemato-Oncological Patients after the Implementation of an Adapted Therapeutic Protocol at a University Hospital in Uruguay

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.

Novel Risk Factors for Venous Thromboembolism (VTE): A Population-Based Case-Control Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only